Innovation Driven,BioCity has established a rich and potential Best-in-Class pipelines targeting therapeutic areas including oncology and Nephropathy.
As a fast-growing clinical-stage biopharmaceutical company with core competitiveness from project establishment to translational medicine and clinical development ,
BioCity is willing to collaborate with its partners to provide patients with new therapeutic drugs and improve their quality of life.
Maximum the value of our product by Working closely to co-develop the global market
On case by case basis , out-license or co-develop products of BioCity
Exploring potential combination treatment with BioCity's core products
Partner
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
Signing ceremony of strategic cooperation memorandum with
AstraZeneca
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China